The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Angiotensin II for the Treatment of Vasodilatory Shock.
Vasodilatory shock that does not respond to high-dose vasopressors is associated with high mortality. We investigated the effectiveness of angiotensin II for the treatment of patients with this condition. ⋯ Angiotensin II effectively increased blood pressure in patients with vasodilatory shock that did not respond to high doses of conventional vasopressors. (Funded by La Jolla Pharmaceutical Company; ATHOS-3 ClinicalTrials.gov number, NCT02338843 .).
-
Multicenter Study Clinical Trial
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran. ⋯ In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947 .).